BTIG Maintains Buy on Carlsmed, Raises Price Target to $24

Benzinga Newsdesk www.benzinga.com Positive 80.5%

Neg 0% Neu 0% Pos 80.5%

BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.

Comments

No comments yet. Be the first!